Evolution of COVID-19 According to Vaccination Status in a Moroccan Cohort

Abstract

Introduction: Since the development of vaccines against the new emerging virus SARSCoV-2, which causes the coronavirus disease 2019 (COVID-19), several fundamental questions remain regarding the efficacy of these vaccines and their impact on the disease, its occurrence and its clinical course. In this sense, the study of the efficiency of the proposed vaccines has become an obligation in order to determine their true influence on COVID-19 in real clinical situation. Materials and Methods: This is a retrospective and prospective cohort study with descriptive and analytical cross-sectional aims conducted in the Avicenna hospital in Marrakech over a period of 50 days, between December 20, 2021 and February 10, 2022, among patients diagnosed as positive for SARS-CoV-2 infection confirmed by RT-PCR. Data collection was performed retrospectively and prospectively on medical records and by telephone calls of the patients diagnosed positive using a pre-established operating form. Results: 512 patients were included during the study period. The average age of the patients was 41 years with a slight male predominance (sex ratio M/F=1.37). 24.4% of our patients had at least one associated comorbidity, with diabetes and hypertension the most frequent comorbidities with a percentage of 15.2% and 9.8% respectively. - 75.8% of the patients included in our study were fully vaccinated against COVID-19, while 24.2% were partially or not vaccinated. The evolution was marked by the occurrence of severe COVID-19 in 3.9% of the cases combined, out of only 1.8% of the fully vaccinated cases developed a severe form compared to 10.5% of the partially or non-vaccinated patients. The analytical study of our results showed that vaccination status and clinical progression had a statistically significant relationship and that complete vaccination was a protective factor against the occurrence of severe COVID-19 disease, although the overall efficacy of complete vaccination against these ........